Skip to main content
. 2012 Sep 17;30(36):4515–4523. doi: 10.1200/JCO.2012.43.4738

Fig 3.

Fig 3.

Distribution of the genetic subsets within European LeukemiaNet genetic groups in younger and older adults with primary acute myeloid leukemia (AML). (A) The favorable group consists of four genetic subsets. The first two subsets are patients with core-binding factor AML (CBF-AML) with either t(8;21) (ie, t(8;21)(q22;q22)/RUNX1-RUNX1T1) or inv(16)/t(16;16) (ie, inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB-MYH11). The second two subsets are patients with cytogenetically normal AML (CN-AML) with either NPM1-mut/FLT3-ITD– (ie, mutated NPM1 without FLT3-ITD [internal tandem duplication]) or CEBPA-mut (ie, mutated CEBPA). (B) The intermediate-I group consists of three genetic subsets of patients with CN-AML and either NPM1-mut/FLT3-ITD+ (ie, mutated NPM1 and FLT3-ITD) or NPM1-wt/FLT3-ITD+ (ie, wild-type NPM1 and FLT3-ITD) or NPM1-wt/FLT3-ITD– (ie, wild-type NPM1 without FLT3-ITD). (C) The intermediate-II group consists of two genetic subsets of patients with either t(9;11) (ie, t(9;11)(p22;q23)/MLLT3-MLL) or other abnormalities (ie, cytogenetic abnormalities not classified as favorable or adverse). (D) The adverse group consists of seven genetic subsets: (1) inv(3)/t(3;3) (ie, inv(3)(q21q26.2) or t(3;3)(q21;q26.2)/RPN1-EVI1), (2) t(6;9) (ie, t(6;9)(p23;q34)/DEK-NUP214), (3) t(v;11) (ie, t(v;11)(v;q23)/MLL rearranged), (4) −5/del(5q) (ie, monosomy of chromosome 5 or deletion of q), (5) −7 (ie, monosomy of chromosome ), (6) abnl(17p) (ie, abnormalities of the short arm or chromosome; no patient had this abnormality in our study), or () “complex karyotype” (ie, a complex karyotype containing three or more cytogenetic abnormalities).